Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2025-10-23 Major Shareholding Noti…
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Renalytix PLC. It details a change in shareholding where UBS Group AG's holdings fell below the 5% threshold. This is a classic regulatory disclosure regarding major share ownership, which falls under the 'Major Shareholding Notification' category.
2025-10-23 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by UBS Group AG regarding their interest in Renalytix PLC. This form is the standard regulatory requirement in the UK for disclosing when a shareholder's voting rights cross a specific threshold. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2025-10-21 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by UBS Group AG regarding its shareholding in Renalytix PLC. This is a regulatory requirement for disclosing significant changes in share ownership (crossing thresholds). According to the provided filing definitions, this falls under 'Major Shareholding Notification'.
2025-10-17 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for shareholders to disclose when their voting rights in a company cross certain thresholds. This is a classic 'Major Shareholding Notification' filing, which corresponds to the MRQ category.
2025-10-17 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a TR-1 notification, which is the standard regulatory form used in the UK for disclosing major shareholding notifications. The text explicitly mentions 'Holding(s) in Company' and 'TR-1 notification', and details the crossing of voting rights thresholds by Harwood Capital LLP. This fits the definition of a Major Shareholding Notification (MRQ).
2025-10-16 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership by Unicorn Asset Management Limited in Renalytix plc, crossing a reporting threshold. This fits the definition of a Major Shareholding Notification (MRQ).
2025-10-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.